Leslie Gewin1,2,3. 1. Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center. 2. Department of Medicine, Veterans Affairs Hospital, Tennessee Valley Healthcare System. 3. Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee, USA.
Abstract
PURPOSE OF REVIEW: Preclinical data suggests that transforming growth factor-β (TGF-β) is arguably the most potent profibrotic growth factor in kidney injury. Despite this, recent clinical trials targeting TGF-β have been disappointing. These negative studies suggest that TGF-β signaling in the injured kidney might be more complicated than originally thought. This review examines recent studies that expand our understanding of how this pleiotropic growth factor affects renal injury. RECENT FINDINGS: There are recent studies showing new mechanisms whereby TGF-β can mediate injury (e.g. epigenetic effects, macrophage chemoattractant). However, more significant are the increasing reports on cross-talk between TGF-β signaling and other pathways relevant to renal injury such as Wnt/β-catenin, YAP/TAZ (transcriptional coactivator with PDZ-binding motif), and klotho/FGF23. TGF-β clearly alters the response to injury, not just by direct transcriptional changes on target cells, but also through effects on other signaling pathways. In T cells and tubular epithelial cells, some of these TGF-β-mediated changes are potentially beneficial. SUMMARY: It is unlikely that inhibition of TGF-β per se will be a successful antifibrotic strategy, but a better understanding of TGF-β's actions may reveal promising downstream targets or modulators of signaling to target therapeutically for chronic kidney disease.
PURPOSE OF REVIEW: Preclinical data suggests that transforming growth factor-β (TGF-β) is arguably the most potent profibrotic growth factor in kidney injury. Despite this, recent clinical trials targeting TGF-β have been disappointing. These negative studies suggest that TGF-β signaling in the injured kidney might be more complicated than originally thought. This review examines recent studies that expand our understanding of how this pleiotropic growth factor affects renal injury. RECENT FINDINGS: There are recent studies showing new mechanisms whereby TGF-β can mediate injury (e.g. epigenetic effects, macrophage chemoattractant). However, more significant are the increasing reports on cross-talk between TGF-β signaling and other pathways relevant to renal injury such as Wnt/β-catenin, YAP/TAZ (transcriptional coactivator with PDZ-binding motif), and klotho/FGF23. TGF-β clearly alters the response to injury, not just by direct transcriptional changes on target cells, but also through effects on other signaling pathways. In T cells and tubular epithelial cells, some of these TGF-β-mediated changes are potentially beneficial. SUMMARY: It is unlikely that inhibition of TGF-β per se will be a successful antifibrotic strategy, but a better understanding of TGF-β's actions may reveal promising downstream targets or modulators of signaling to target therapeutically for chronic kidney disease.
Authors: Robert Koesters; Brigitte Kaissling; Michel Lehir; Nicolas Picard; Franziska Theilig; Rolf Gebhardt; Adam B Glick; Brunhilde Hähnel; Hiltraud Hosser; Hermann-Josef Gröne; Wilhelm Kriz Journal: Am J Pathol Date: 2010-07-08 Impact factor: 4.307
Authors: Nicholas W Clavin; Tomer Avraham; John Fernandez; Sanjay V Daluvoy; Marc A Soares; Arif Chaudhry; Babak J Mehrara Journal: Am J Physiol Heart Circ Physiol Date: 2008-10-10 Impact factor: 4.733
Authors: Jai Prakash; Martin H de Borst; Annemiek M van Loenen-Weemaes; Marie Lacombe; Frank Opdam; Harry van Goor; Dirk K F Meijer; Frits Moolenaar; Klaas Poelstra; Robbert J Kok Journal: Pharm Res Date: 2008-01-09 Impact factor: 4.200
Authors: Sara Lovisa; Valerie S LeBleu; Björn Tampe; Hikaru Sugimoto; Komal Vadnagara; Julienne L Carstens; Chia-Chin Wu; Yohannes Hagos; Birgitta C Burckhardt; Tsvetelina Pentcheva-Hoang; Hersharan Nischal; James P Allison; Michael Zeisberg; Raghu Kalluri Journal: Nat Med Date: 2015-08-03 Impact factor: 53.440
Authors: Han Lai; Anqun Chen; Hong Cai; Jia Fu; Fadi Salem; Yu Li; John C He; Detlef Schlondorff; Kyung Lee Journal: Kidney Int Date: 2020-04-26 Impact factor: 10.612